Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.00388-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Lee S Gottesdiener und 31 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamase Inhibitors, Carbapenems, Pseudomonas aeruginosa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Novel β-lactam/β-lactamase inhibitors (βL/βLIs) are important therapies for carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, the global extent of resistance to these agents and the impact of resistance on patient outcomes are unclear. We therefore evaluated patients with CRPA isolates at 35 hospitals (nine countries) from December 2018 to November 2019. Antimicrobial susceptibility testing was performed at a central laboratory by agar dilution for ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) and by broth microdilution for imipenem-relebactam (I/R). Characteristics and outcomes, including desirability of outcome rankings (DOOR), were compared between patients infected with isolates not susceptible vs susceptible to each agent. Of 800 CRPA isolates, susceptibility to C/T, CZA, and I/R was 69%, 67%, and 33%, respectively. USA isolates ( n = 526) were more frequently susceptible to these agents than isolates from other countries ( n = 274; C/T: 83% vs 42%; CZA: 77% vs 47%; I/R: 37% vs 23%; P < 0.001 for each comparison) and isolates with carbapenemases ( n = 157) were less frequently susceptible than isolates without carbapenemases ( n = 643; C/T: 7% vs 84%; CZA: 24% vs 77%; I/R: 6% vs 39%; P < 0.001 for each comparison). Thirty-day mortality and DOOR were similar overall in patients infected with isolates not susceptible vs susceptible to each βL/βLI. However, the adjusted probability of a better DOOR outcome for a randomly selected patient with bacteremia due to a C/T-not susceptible vs -susceptible isolate was 38.2% (95% confidence interval, 25.6%–52.7%). Resistance to novel βL/βLIs, especially I/R, is common in CRPA, particularly outside the USA and in carbapenemase-producing isolates. Additional treatment options are needed for CRPA infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, New York, USA.
- NewYork-Presbyterian Hospital, New York, New York, USA.
- The Biostatistics Center, George Washington University, Rockville, Maryland, USA.
- Mayo Clinic, Rochester, Minnesota, USA.
- Houston Methodist Hospital, Houston, Texas, USA.
- Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Cesar A Arias, Bettina C Fries, Jinnethe Reyes, Liang Chen, Barry N Kreiswirth, Maria Virginia Villegas, David L Paterson, Robert A Bonomo, Vance G Fowler, Robin Patel, David van Duin, Michael J Satlin
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Gottesdiener, L. S., Li, Y., Greenwood-Quaintance, K. E., Komarow, L., Arias, C. A., Cober, E., Herc, E. S., Kaye, K. S., Huskins, W. C., Figueroa, J., Vilchez, S., Fries, B. C., Leroi, M., McCarty, T. P., Rioseco, M. L., Munita, J. M., Stryjewski, M. E., Reyes, J., Chen, L., …, & Antibacterial Resistance Leadership Group (2026). Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00388-25
Vancouver
Gottesdiener LS, Li Y, Greenwood-Quaintance KE, Komarow L, Arias CA, Cober E, et al. Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00388-25
BibTeX
@article{Gottesdiener2026,
author = {Gottesdiener, Lee S and Li, Yixuan and Greenwood-Quaintance, Kerryl E and Komarow, Lauren and Arias, Cesar A and Cober, Eric and Herc, Erica S and Kaye, Keith S and Huskins, W Charles and Figueroa, Jairo and Vilchez, Samuel and Fries, Bettina C and Leroi, Marcel and McCarty, Todd P and Rioseco, María L and Munita, Jose M and Stryjewski, Martin E and Reyes, Jinnethe and Chen, Liang and Kreiswirth, Barry N and Hill, Carol and Baum, Keri and Villegas, Maria Virginia and Paterson, David L and Bonomo, Robert A and Chambers, Henry F and Fowler, Vance G and Patel, Robin and Doi, Yohei and van Duin, David and Satlin, Michael J and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
title = {Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.00388-25}
}
EUVIMED